Tenderwize
Zurück zur Suche

Open-house rebate agreement for Eltrombopag

AOK Bayern - Die Gesundheitskasse·München, Germany·Deadline Sep 05, 2026 · 8 days left·Open·Supplies·Framework
Registrieren zum SpeichernOpen documents
Originaltitel der Bekanntmachung

Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Eltrombopag, ATC B02BX05

62/100

Opportunity Score

Needs reviewMedium complexity
SuppliesFrameworkOpen
Warum diese Bewertung?

Chance

62 / 100

Komplexität

48 / 100

Risikofaktoren

Submission is only valid if the chosen format requirements are met: handwritten paper originals in duplicate or electro...

Participation is restricted to pharmaceutical companies, and suitability must be demonstrated by a signed declaration o...

Submission deadline in 8 days

Tiefe Portfolioanalyse

Tiefe Analyse der Unternehmenspassung

Verwendet:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Überblick

Moderate opportunity

Wichtige Fakten

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Oct 2026
  • Non-exclusive rebate agreements for the active substance Eltrombopag (ATC B02BX05).
  • Supply contract for pharmaceutical products.
Vollständige Zusammenfassung anzeigen

This is an open-house pharmaceutical supply arrangement for Eltrombopag (ATC B02BX05) offered by AOK Bayern to all interested pharmaceutical companies that meet the stated eligibility requirement. It is not a competitive award procedure in the usual sense: no selection among bidders, identical non-negotiable contract terms, and no explicit award criteria. Contracting is possible throughout the term, with the latest contract conclusion date stated as 2026-09-05. Submission is possible electronically with a qualified electronic signature via DTVP or in paper form in duplicate originals.

Risiken

Submission is only valid if the chosen format requirements are met: handwritten paper originals in duplicate or electro...

Participation is restricted to pharmaceutical companies, and suitability must be demonstrated by a signed declaration o...

Submission deadline in 8 days

Analyse kann unvollständig sein

Nur ein Teil der Vergabeunterlagen wurde analysiert. Weitere Anforderungen, Zertifikate oder Einreichungsdokumente können in den übrigen Unterlagen enthalten sein.

Wichtige Anforderungen

Technical

  • The contract and the annex 'Festlegung der vertragsgegenständlichen Arzneimittel' must be completed and signed.

Eligibility

  • Only pharmaceutical companies are eligible as potential contract partners.

Administrative

  • A signed declaration of reliability (Eigenerklärung zur Zuverlässigkeit) must be submitted.

Auftraggeber

Ort

München, DEU

Website

www.aok.de

Auftraggeberprofil

Profil öffnen

Kennung

DE811695320

Tätigkeit

Health

Lose (1)

LOT-0001

Open-house rebate agreement for Eltrombopag

Single lot for non-exclusive open-house rebate agreements for the medicinal product Eltrombopag, ATC B02BX05. Scope is pharmaceutical supplies in Germany (place of performance: DEU, DE212). The lot is described as an open-house model with identical, non-individually negotiated contract terms.

SuppliesFrameworkEU fundedElectronic submission

Ort

DE212, Germany

Dauer

Oct 2024 - Oct 2026

Kategorie

Pharmaceutical products

Frist

Deadline Sep 05, 2026

Vergabedetails

Veröffentlichungsdatum
16 Sep 2024
Sprachen
German

Referenzmetadaten

Rechtsgrundlage
32014L0024

Referenz-IDs

Ausschreibungs-ID
558406-2024

Dokumente (2)

Vergabedokument 1Einreichungsportal 1

Ähnliche Ausschreibungen

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta

Aug 30